Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines

被引:215
|
作者
Medina, Pedro P. [1 ]
Romero, Octavio A. [1 ]
Kohno, Takashi [2 ]
Montuenga, Luis A. [3 ]
Pio, Ruben [3 ]
Yokota, Jun [2 ]
Sanchez-Cespedes, Montse [1 ]
机构
[1] CNIO, Mol Pathol Programme, Lung Canc Grp, Madrid 28029, Spain
[2] Natl Canc Ctr, Div Biol, Tokyo, Japan
[3] Univ Navarra, Div Oncol, CIMA, E-31080 Pamplona, Spain
关键词
BRG1; SMARCA4; tumor suppressor gene; chromatin remodeling; lung cancer; MYC amplification;
D O I
10.1002/humu.20730
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Components of the SWI/SNF chromatin,remodeling complex, such as INI1, are inactivated in human cancer and, thus, act as tumor suppressors. Here we screened for mutations the entire coding sequence of BRG1 (SMARCA4), which encodes the ATPase of the complex, in 59 lung cancer cell lines of the most common histopathological types. Mutations were detected in 24% of the cancer cell lines, many of them in cells commonly used for lung cancer research. All mutations were homozygous and most predicted truncated proteins. The alterations were significantly more frequent in the non-small-cell lung cancer (NSCLC) type (13/37, 35%) as compared to the small,cell lung cancer (SCLC) type (1/19, 5%) (P<0.05; Fisher's Exact test) and BRG1 was the fourth most frequently altered gene in NSCLC cell lines. BRG1 mutations coexisted with mutations/deletions at KRAS, LKB1, NRAS, P16, and P53. However, alterations at BRG1 always occurred in the absence of MYC amplification, suggesting a common role in lung cancer development. In conclusion, our data strongly support that BRG1 is a bona fide tumor suppressor and a major factor in lung tumorigenesis.
引用
收藏
页码:617 / 622
页数:6
相关论文
共 50 条
  • [21] Immunophenotypical Analysis of SMARCA4 (BRG1) Deficient Non-Small Cell Lung Carcinoma Diagnosed on Cytology Specimens
    Ogunbona, Oluwaseun
    Lubin, Daniel
    Reid, Michelle
    Van Nostrand, Keriann
    Schneider, Frank
    Shi, Qiuying
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 257 - 258
  • [22] BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways
    Jubierre, L.
    Soriano, A.
    Planells-Ferrer, L.
    Paris-Coderch, L.
    Tenbaum, S. P.
    Romero, O. A.
    Moubarak, R. S.
    Almazan-Moga, A.
    Molist, C.
    Roma, J.
    Navarro, S.
    Noguera, R.
    Sanchez-Cespedes, M.
    Comella, J. X.
    Palmer, H. G.
    Sanchez de Toledo, J.
    Gallego, S.
    Segura, M. F.
    ONCOGENE, 2016, 35 (39) : 5179 - 5190
  • [23] BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways
    L Jubierre
    A Soriano
    L Planells-Ferrer
    L París-Coderch
    S P Tenbaum
    O A Romero
    R S Moubarak
    A Almazán-Moga
    C Molist
    J Roma
    S Navarro
    R Noguera
    M Sánchez-Céspedes
    J X Comella
    H G Palmer
    J Sánchez de Toledo
    S Gallego
    M F Segura
    Oncogene, 2016, 35 : 5179 - 5190
  • [24] Cellular Expression of Smarca4 (Brg1)-regulated Genes in Zebrafish Retinas
    Hensley, Monica R.
    Emran, Farida
    Bonilla, Sylvia
    Zhang, Liyun
    Zhong, Wenxuan
    Grosu, Paul
    Dowling, John E.
    Leung, Yuk Fai
    BMC DEVELOPMENTAL BIOLOGY, 2011, 11
  • [25] RHABDOID TUMOR PREDISPOSITION SYNDROME DUE TO MUTATION OF BRG1/SMARCA4
    Fruewaldi, M. C.
    Schneppenheim, R.
    Gesk, S.
    Hasselblatt, Ni.
    Vater, I.
    Kordes, U.
    Leuschner, I.
    Subero, M.
    Obser, T.
    Oyen, F.
    Siebert, R.
    NEURO-ONCOLOGY, 2010, 12 (06) : II63 - II63
  • [26] Massive Parallel DNA Pyrosequencing Analysis of the Tumor Suppressor BRG1/SMARCA4 in Lung Primary Tumors
    Rodriguez-Nieto, Salvador
    Canada, Andres
    Pros, Eva
    Pinto, Ana I.
    Torres-Lanzas, Juan
    Lopez-Rios, Fernando
    Sanchez-Verde, Lydia
    Pisano, David G.
    Sanchez-Cespedes, Montse
    HUMAN MUTATION, 2011, 32 (02) : E1999 - E2017
  • [27] BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines
    M. Cuadros
    V. Sánchez-Martín
    A. Herrera
    C. Baliñas
    J. Martín-Padrón
    L. Boyero
    P. Peinado
    P. P. Medina
    Clinical and Translational Oncology, 2017, 19 : 1010 - 1017
  • [28] Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
    Shaykevich, Aaron
    Chae, Danbee
    Silverman, Isaac
    Bassali, Jeremy
    Louloueian, Netanel
    Siegman, Alexander
    Bandyopadhyaya, Gargi
    Goel, Sanjay
    Maitra, Radhashree
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 229 - 239
  • [29] Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
    Aaron Shaykevich
    Danbee Chae
    Isaac Silverman
    Jeremy Bassali
    Netanel Louloueian
    Alexander Siegman
    Gargi Bandyopadhyaya
    Sanjay Goel
    Radhashree Maitra
    Investigational New Drugs, 2024, 42 : 229 - 239
  • [30] Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer (vol 2, pg 64, 2008)
    Medina, Pedro P.
    Sanchez-Cespedes, Montse
    EPIGENETICS, 2008, 3 (04) : 234 - 234